| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | FH; HF; HF1; HF2; HUS; FHL1; AHUS1; AMBP1; ARMD4; ARMS1; CFHL3 |
| WB Predicted band size | 139 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CFH |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SCGB2A1抗体的3篇参考文献及其简要摘要：
---
1. **文献名称**: *SCGB2A1 (Mammaglobin-A) as a Novel Biomarker for Breast Cancer Metastasis*
**作者**: Watson MA, et al.
**摘要**: 该研究验证了SCGB2A1抗体在乳腺癌组织中的特异性，发现其高表达与淋巴结转移相关，提示其作为乳腺癌转移预测标志物的潜力。抗体通过免疫组化方法应用于临床样本分析。
2. **文献名称**: *Differential Expression of SCGB2A1 in Lung Adenocarcinoma and Its Diagnostic Utility*
**作者**: Kim S, et al.
**摘要**: 研究利用SCGB2A1抗体检测肺腺癌组织中的蛋白表达，发现其在特定亚型中显著上调，表明该抗体可用于辅助肺癌的病理分型及鉴别诊断。
3. **文献名称**: *SCGB2A1 Antibody-Based Circulating Tumor Cell Detection in Metastatic Carcinomas*
**作者**: Bernhardt SM, et al.
**摘要**: 开发了一种基于SCGB2A1抗体的血液检测技术，用于识别乳腺癌和卵巢癌患者外周血中的循环肿瘤细胞，证明其高敏感性和临床监测价值。
---
以上文献涵盖SCGB2A1抗体在癌症诊断、分型及转移监测中的应用，具体细节建议通过PubMed或期刊数据库查询原文。
Secretoglobin family 2A member 1 (SCGB2A1), also known as mammaglobin-B, is a small secretory protein belonging to the secretoglobin superfamily. It is primarily expressed in glandular epithelial tissues, including the mammary glands, salivary glands, and respiratory tract. SCGB2A1 forms disulfide-linked heterodimers with lipophilin proteins, contributing to its stability and secretion into extracellular fluids. Its exact physiological role remains unclear, though it is hypothesized to participate in immune modulation, inflammation regulation, or lipid transport.
SCGB2A1 antibodies are valuable tools for investigating its expression patterns and function in both normal and pathological conditions. In research, these antibodies are widely used in immunohistochemistry (IHC), Western blotting, and ELISA to detect SCGB2A1 in tissue samples or bodily fluids. Notably, SCGB2A1 has gained attention as a potential biomarker in oncology. Overexpression has been reported in breast cancer, ovarian cancer, and other malignancies, correlating with tumor progression and metastasis. Its restricted expression in healthy tissues makes it a candidate for targeted therapy or diagnostic applications.
Commercial SCGB2A1 antibodies are typically validated for specificity using knockout controls or siRNA-mediated silencing. Researchers should verify cross-reactivity with homologous proteins (e.g., mammaglobin-A) and optimize protocols for specific experimental models. Ongoing studies explore its role in tumor microenvironment interactions and as a liquid biopsy marker, highlighting its translational potential in precision medicine.
×
